Resalis Therapeutics
Resalis Therapeutics is developing first-in-class anti-miR compounds to address high unmet medical needs in liver diseases, metabolic disorders, and cancer using a multi-pathway approach.
1
Funding Rounds
$11.0m
Money raised
Overview
Resalis Therapeutics is developing first-in-class anti-miR compounds to address high unmet medical needs in liver diseases, metabolic disorders, and cancer using a multi-pathway approach.
- Website:
Funding series
Funding Series Analysis
The company Resalis Therapeutics has raised a total of $11m in funding over 1 rounds.
Key Insights:
- Resalis Therapeutics February 2023 Seed Funding Round: $11m
Resalis Therapeutics February 2023 Seed Funding Round
$11m
Industries
Resalis Therapeutics is active in the following industries: